Study on the Clinical Efficacy of Levofloxacin Combined with Ambroxol in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Infection
Abstract
Objective: To investigate the clinical efficacy of levofloxacin combined with ambroxol in the treatment of elderly patients with chronic obstructive pulmonary disease (COPD) and pulmonary infection. Methods: A total of 80 elderly COPD patients with pulmonary infection, treated between December 2022 and November 2023, were randomly divided into a control group and an observation group, with 40 cases in each group. The control group was treated with levofloxacin hydrochloride, while the observation group received ambroxol hydrochloride injection in addition to the treatment in the control group. Laboratory indices (white blood cell count, procalcitonin, C-reactive protein, and apolipoprotein E levels), imaging-based pulmonary lesion absorption time, hospital stay, and incidence of adverse reactions were compared between the two groups. Results: After treatment, the biochemical indices of the observation group were significantly lower than those of the control group, with highly significant differences (P < 0.001). Compared to the control group, the imaging-based pulmonary lesion absorption time and hospital stay of the observation group were significantly shorter (P < 0.001). Additionally, the incidence of adverse reactions in the observation group was significantly lower than in the control group (P < 0.05). Conclusion: Levofloxacin combined with ambroxol demonstrates advantages in improving biochemical indices, shortening imaging-based pulmonary lesion absorption time and…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.